Intermune Eyes Settlement Over Off-Label Marketing
Biotechnology company Intermune Inc. is preparing to pay as much as $30 million to settle allegations from federal prosecutors that it illegally promoted a drug for a use not approved by...To view the full article, register now.
Already a subscriber? Click here to view full article